Yumeng Li1, Chuan Wang1, Zhenjie Sun1, Jian Xiao1, Xiaoliang Yan1, Yuqing Chen1, Jian Yu2, Yimou Wu1. 1. Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Institution of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang 421001, People's Republic of China. 2. Department of Experimental Zoology, Hengyang Medical College, University of South China, Hengyang 421001, People's Republic of China.
Abstract
BACKGROUND: Chlamydia psittaci is a zoonotic bacteria closely associated with psittacosis/ornithosis. Vaccination has been recognized as the best way to inhibit the spread of C. psittaci due to the majority ignored of infections. The optimal Chlamydia vaccine was obstructed by the defect of single immunization route and the lack of availability of nontoxic and valid adjuvants. METHODS: In this study, we developed a novel immunization strategy, simultaneous (SIM) intramuscular (IM) and intranasal (IN) administration of a C. psittaci antigens (Ags) adjuvanted with chitosan nanoparticles (CNPs). And SIM-CNPs-Ags were used to determine the different types of immune response and the protective role in vivo. RESULTS: CNPs-Ags with zeta-potential values of 13.12 mV and of 276.1 nm showed excellent stability and optimal size for crossing the mucosal barrier with high 71.7% encapsulation efficiency. SIM-CPN-Ags mediated stronger humoral and mucosal responses by producing meaningfully high levels of IgG and secretory IgA (sIgA) antibodies. The SIM route also led to Ags-specific T-cell responses and increased IFN-γ, IL-2, TNF-α and IL-17A in the splenocyte supernatants. Following respiratory infection with C. psittaci, we found that SIM immunization remarkably reduced bacterial load and the degree of inflammation in the infected lungs and made for a lower level of IFN-γ, TNF-α and IL-6. Furthermore, SIM vaccination with CNPs-Ags had obviously inhibited C. psittaci disseminating to various organs in vivo. CONCLUSION: SIM immunization with CNPs-adjuvanted C. psittaci Ags may present a novel strategy for the development of a vaccine against the C. psittaci infection.
BACKGROUND: Chlamydia psittaci is a zoonotic bacteria closely associated with psittacosis/ornithosis. Vaccination has been recognized as the best way to inhibit the spread of C. psittaci due to the majority ignored of infections. The optimal Chlamydia vaccine was obstructed by the defect of single immunization route and the lack of availability of nontoxic and valid adjuvants. METHODS: In this study, we developed a novel immunization strategy, simultaneous (SIM) intramuscular (IM) and intranasal (IN) administration of a C. psittaci antigens (Ags) adjuvanted with chitosan nanoparticles (CNPs). And SIM-CNPs-Ags were used to determine the different types of immune response and the protective role in vivo. RESULTS: CNPs-Ags with zeta-potential values of 13.12 mV and of 276.1 nm showed excellent stability and optimal size for crossing the mucosal barrier with high 71.7% encapsulation efficiency. SIM-CPN-Ags mediated stronger humoral and mucosal responses by producing meaningfully high levels of IgG and secretory IgA (sIgA) antibodies. The SIM route also led to Ags-specific T-cell responses and increased IFN-γ, IL-2, TNF-α and IL-17A in the splenocyte supernatants. Following respiratory infection with C. psittaci, we found that SIM immunization remarkably reduced bacterial load and the degree of inflammation in the infected lungs and made for a lower level of IFN-γ, TNF-α and IL-6. Furthermore, SIM vaccination with CNPs-Ags had obviously inhibited C. psittaci disseminating to various organs in vivo. CONCLUSION: SIM immunization with CNPs-adjuvanted C. psittaci Ags may present a novel strategy for the development of a vaccine against the C. psittaci infection.
Authors: Shahneaz Ali Khan; Adam Polkinghorne; Courtney Waugh; Jon Hanger; Jo Loader; Kenneth Beagley; Peter Timms Journal: Vaccine Date: 2015-12-30 Impact factor: 3.641
Authors: Michael R Knittler; Angela Berndt; Selina Böcker; Pavel Dutow; Frank Hänel; Dagmar Heuer; Danny Kägebein; Andreas Klos; Sophia Koch; Elisabeth Liebler-Tenorio; Carola Ostermann; Petra Reinhold; Hans Peter Saluz; Gerhard Schöfl; Philipp Sehnert; Konrad Sachse Journal: Int J Med Microbiol Date: 2014-06-28 Impact factor: 3.473
Authors: Luiza A Frank; Giuseppina Sandri; Francesca D'Autilia; Renata V Contri; Maria Cristina Bonferoni; Carla Caramella; Alejandro G Frank; Adriana R Pohlmann; Silvia S Guterres Journal: Int J Nanomedicine Date: 2014-06-28
Authors: Jenny Bode; Pavel Dutow; Kirsten Sommer; Katrin Janik; Silke Glage; Burkhard Tümmler; Antje Munder; Robert Laudeley; Konrad W Sachse; Andreas Klos Journal: PLoS One Date: 2012-11-26 Impact factor: 3.240